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Abstract A truncated form of the membrane-type matrix 
metalloproteinase-1 [(AlaZ1-Ile318)proMTl-MMP] lacking the 
hemopexin-like and trans-membrane domain was produced in E. 
coli. We demonstrate that the recombinant proenzyme was 
autoproteolytically processed to a fully active catalytic domain 
with N-terminal Ile114. The catalytic domain of MTl-MMP 
initiated the activation of progelatinase A and progelatinase A 
complexed with tissue inhibitor of metalloproteinases-2 (TIMP- 
2). As a typical soluble metalloproteinase it was able to cleave 
physiologic as well as synthetic substrates. Our kinetic data 
demonstrate that TIMP-2 is a potent inhibitor for the 
recombinant enzyme. 
Key words: Matrix metalloproteinase; Gelatinase A; 
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1. Introduction 
The matrix metalloproteinases (MMPs, matrixins) comprise 
a family of zinc proteinases capable of remodeling, repairing 
and destroying connective tissue via hydrolysis of matrix pro- 
teins. The matrixin family is divided into six subgroups, 
namely the collagenases, gelatinases, stromelysins, matrilysin, 
metalloelastase and membrane-type matrix metalloproteinases 
[l-3]. Members of the matrix metalloproteinase family share 
several structural and functional properties, but they differ to 
some extent with regard to substrate specificity. There is in- 
creasing evidence that a disregulated expression of MMPs 
leads to many pathophysiological events connected to extra- 
cellular matrix destruction, cancer invasion and metastasis [4- 
61. Type IV collagen is the major structural component of 
basement membranes [7,8]. The close correlation between 
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the type IV collagenolytic activities of MMP-2 (gelatinase A) 
and MMP-9 (gelatinase B) and the metastatic progression of 
various tumors suggests that their activator is the key enzyme 
which triggers the metastatic process. ProMMPs can be acti- 
vated in vitro by organomercury compounds and individual 
species by certain serine proteinases such as trypsin, plasmin, 
plasma kallikrein, leukocyte elastase or cathepsin G [9]. Many 
investigators have reported that in vivo a ‘plasma membrane 
dependent’ mechanism is responsible for proMMP activation. 
Like other MMPs, progelatinase A is synthesized and secreted 
from the cells as an inactive precursor. In vitro it is readily 
activated by 4-aminophenylmercuric acetate [lo], but progela- 
tinase A is unique among MMPs in that it has proved to be 
resistant to proteolytic activation by both serine proteinases 
and other MMPs [lo-121. Sato et al. recently isolated a cDNA 
from a human placenta cDNA library which coded for a 
novel MMP family member with a transmembrane domain. 
Membrane-type MMP-1 (MTl-MMP) was shown to be loca- 
lized on cell surfaces [13], and converted progelatinase A to 
the 62 kDa fully active form, indicating that MTl-MMP is a 
physiological activator of gelatinase A. Cao and co-workers 
reported that the transmembrane domain (TM) at the C-ter- 
minus of MTl-MMP is essential for progelatinase A activa- 
tion because the activity was abolished by truncation of the 
membrane linker [14]. The resulting MTl-MMP fragment did 
not activate proMMP-2. In this article we describe the bacter- 
ial expression of MTl-MMP without the hemopexin-like do- 
main and a simple procedure for in vitro folding and genera- 
tion of the active enzyme. In contrast to the above mentioned 
work we report that the catalytic domain of MTl-MMP 
(cdMTl-MMP) is an efficient activator of progelatinase A 
as well as of the progelatinase A/TIMP-2 complex. Thus, 
neither the hemopexin-like domain nor the TM domain is 
required to activate the proenzyme. Furthermore, our study 
indicates that the truncated proform of MTl-MMP in vitro 
may be processed by autocleavage of two amino acids C-ter- 
minal of the described processing site for the full-length en- 
zyme [15]. Our kinetic study shows that proteolytic activity of 
cdMTl-MMP is specifically effected by TIMP-2. 
2. Materials and methods 
2.1. PCR amplification. bacterial expression and purification of 
(AlaZ’-Il~~s)proMTI-MMP 
The cDNA for the full-length enzyme was generously provided by 
Dr. Bartnik (Hoechst AG, Wiesbaden). The cDNA fragment encod- 
ing AlaZ1-Ile318 of proMTl-MMP (numbering includes the signal pep- 
tide sequence) was amplified as one product from cDNA by PCR 
using sense primers with a unique NdeI restriction site and antisense 
primers with a unique BamHI site. The NdeI-BamHI fragment encod- 
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ing (Ala2’-Ile318)proMT1-MMP was subcloned between the NdeI and 
BamHI sites of the T7 expression vector pETl la (Novagen) and was 
used to transfect E. coli strain BL21[DE3] [16]. (AlaZ’-Ile318)proMTl- 
MMP was expressed as insoluble inclusion body material. Solubiliza- 
tion was achieved by resuspending the inclusion bodies in buffer (50 
mM Tris-HC1 pH 8.5, 6 M urea, 1 mM EDTA, 150 mM 2-mercap- 
toethanol) with Ultra-Turrax treatment. The enzyme was purified 
using a Sephacryl S-200 column (Pharmacia) equilibrated with S-200 
buffer (50 mM Tris-HCl pH 8.5, 4 M urea, 200 mM NaCl, 80 mM 2- 
mercaptoethanol). The eluted protein was dialyzed twice against 5 1 
PBS buffer containing 100 pM ZnCl?. Under these conditions. the 
recombinant protein remained soluble and was .correctly folded. 
2.2. Gelatin zymography 
Zymography (substrate gel electrophoresis) was conducted with 
0.1% gelatin polymerized into standard Laemmli SDS gels (10% acryl- 
amide) and samples were applied without reduction, as previously 
described [17,18]. SDS gels were run at 20 mA. The SDS was removed 
after electrophoresis by washing the gels in 2.5% Triton X-100 for 30 
min with one change-of washing. The gelatin and casein gels were 
incubated at 37°C for 2 h in incubation buffer (5 mM Tris-HCI DH 
7.5, 200 mM NaCl, 10 mM CaClz and 100 PM‘ ZnClz). The gel&i- 
nolytic and caseinolytic activities were visualized by staining the gels 
with 0.01% Coomassie brilliant blue R 250 in ethanol/acetic acid/ 
water (3: 1:6, v:v:v) and destaining in water overnight. Zones of pro- 
teinase activity were detected as negatively stained bands. Gelatinoly- 
tic activity was quantitated by densitometric measurement of the 
bands seen on the gels. 
2.3. Activation of progelatinase A and progelatinase AITIMP-2 
complex 
Progelatinase A (proMMP-2. 72kDa type IV gelatinase, EC 
3.4.24.24) and progelatinase AjTIMP-2 complex were prepared ac- 
cording to an established procedure [19]. The assay buffer (used in 
all assays, unless otherwise noted) was 20 mM Tris-HC1 pH 7.3, 100 
mM NaCl, 5 mM CaClz, 100 PM ZnCl*, 0.02% NaNs. Maximum 
gelatinase A activity was generated by the incubation of 7.5 ~1 pro- 
gelatinase A (15.6 pmol) with 1.5 11 cdMTl-MMP (4.2 pmol) at 37°C 
for 90 min. The activation of progelatinase A complexed with TIMP-2 
was performed with an excess of cdMTl-MMP. 
2.4. Kinetic studies 
Bovine TIMP-2 was kindly provided by Dr. Calvete (Medizinische 
Hochschule Hannover, Hannover, Germany). The (7-methoxycou- 
marin-4-yl)acetyl-Pro-Leu-Gly-Leu-(3-[2,4-dinitrophenyl]-L-2,3-diami- 
no-propionyl)-Ala-Arg-NH2 (Mea substrate) [20] is an internally 
quenched fluorescent peptide cleaved by various matrix metallopro- 
teinases at the Gly-Leu bond. Fluorimetric analysis was carried out 
using a Perkin-Elmer LS50 B spectrofluorimeter at 25°C. Fluorescence 
was determined at an excitation wavelength of 328 nm and emission 
at 393 nm. For the Km determination the assay mixture contained 330 
ng cdMTl-MMP and different concentrations (0.17-0.43 pmolll) of 
substrate (100 &ml in 15% DMSO) in 2 ml of assay buffer (20 mM 
Tris-HCI pH 7.3, 100 mM NaCl, 5 mM CaC12, 100 pM ZnClz, 0.02% 
NaN3). The initial rate of cleavage of Mca-Pro-Leu-Gly-Leu-Dpa- 
Ala-Arg-NH2 measured over 100 s was proportional to the substrate 
concentration. The assay of the inhibition of cdMTl-MMP by bovine 
TIMP-2 was carried out by preincubating the cdMTl-MMP (14 
nmol) and TIMP-2 (O-9 nM) in assay buffer at 37°C for 15 min. 
Activity was measured for three different Mea peptide substrate con- 
centrations at 25°C by following release of fluorescence with time. 
2.5. Amino acid sequence determination 
Amino-terminal sequence determinations were performed as pub- 
lished [21] using a microsequencer (Model1 810, Knauer, Berlin, Ger- 
many) and a modification of the method of Hunkapiller [22]. 
3. Results 
3.1. PuriJication and activation of 
(Ala21-Ile318)proMTl-MMP 
The coding region of (Ala21-Ile318)proMT1-MMP was am- 
plified by PCR and expressed in E. coli utilizing the inducible 
T7 polymerase PET system. The recombinant protein was 
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Fig. 1. A: SDS-PAGE analysis of the purification of recombinant 
(Ala21-Ile318)proMT1-MMP following Sephadex S-200 gel chroma- 
tography. The homogeneity is documented after silver staining. 
Lane I : protein M, markers (low range standards); lane 2: purified 
(Ala21-Ile318)proMT1-MMP under denaturating conditions; lane 3: 
totally activated cdMTl-MMP followed by incubation at room tem- 
perature overnight. B: SDS-PAGE of the autoproteolytic activation 
of (Ala2’~Ile318)proMT1-MMP under non-denaturating conditions. 
Aliquots of the refolded purified enzyme were incubated at room 
temperature over a period of 4 h and the reactions were terminated 
by addition of sample buffer (50 mM Tris-HCl pH 7.5, 30 mM 
NaCl, 5 M urea, 1% (v/v) 2-mercaptoethanol, 1% (w/v) SDS, 0.05% 
(w/v) BPB). Lane 1: protein markers (low range standards); lane 2: 
sample after concentration by ultrafiltration, maintained at 4°C; 
lanes 3-7: samples after incubation at room temperature for 15, 30, 
60, 90 and 120 min, respectively. 
routinely accumulated in inclusion bodies to a level of 20% 
of the total wet weight of the E. coli mass. The inclusion body 
fraction was recovered from lysed bacteria, solubilized in 6 M 
urea and purified to approximately 95% homogeneity by Se- 
phadex S-200 gel permeation chromatography as determined 
by reduced SDS-PAGE. The proenzyme migrated at the ex- 
pected M, of 33.000 under reducing conditions. The N-ter- 
minal amino acid sequence of (Ala21-Ile31s)proMT1-MMP 
(45 cycles) was found to be identical to the predicted propep- 
tide sequence for the wild-type enzyme defined by Takino et 
al. [23]. In a typical purification 0.18 g of recombinant (Ala’l- 
Ile318)proMT1-MMP was purified from 1 1 of culture medium 
(Fig. 1A). Folding of the purified protein to the active enzyme 
was achieved by repeated dialysis against PBS buffer contain- 













Fig. 2. Activation of progelatinase A by cdMTl-MMP. A: Aliquots 
of progelatinase A (15.6 pmol) were incubated with cdMTl-MMP 
(4.2 pmol) at various times and then subjected to SDS-PAGE (10% 
acrylamide). Lane 1: protein M, markers (wide range standards); 
lane 2: progelatinase A (control); lane 3: cdMTl-MMP; lanes 47: 
reaction mixture after exposure to cdMTl-MMP at 37°C for 15, 30, 
60 and 90 min. B: Gelatin zymogram of progelatinase A activated 
by cdMTl-MMP. 150 ng progelatinase A was incubated with 100 
ng of cdMTl-MMP for 30 min at 37°C. Lane 1: control: progela- 
tinase A in the absence of cdMTl-MMP. Lanes 2-5: progelatinase 
A after incubation with cdMTl-MMP for 5, 15, 30 and 60 min. 
ing 100 FM ZnClz. During the refolding procedure and the 
following protein reconcentration the truncated form of 
proMTl-MMP immediately autoactivated via successive 
cleavages of the propeptide to yield the stable active form 
of the catalytic domain. Maximal activated cdMTl-MMP 
was stable without loss of activity even after storage at 
23°C for several days, although the proenzyme showed spon- 
taneous autoproteolytic activation when stored at 4°C. Dur- 
ing activation (Ala21-Ile3’8)proMTl-MMP of h4, 33000 was 
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processed initially to a major molecule of about M, 24000 
and was then converted to the minor 22500 species (Fig. 
1B). Both species showed proteolytic activity in gelatin (or 
casein) substrate gels. N-terminal amino acid sequencing of 
the products revealed that in both samples the Ala113-Ile114 
peptide bond, two amino acids C-terminal of the RRKR se- 
quence - a potential processing site for subtilisin-like enzymes 
_ was cleaved. The generation of the minor form originates 
from an additional cleavage at the C-terminal site of the re- 
combinant variant of MTl-MMP. Interestingly, the identified 
N-terminus is not identical with that reported for the proc- 
essed full-length enzyme at Tyr112 [15,24]. 
3.2. Activation of progelatinase A and progelatinase A 
complexed with TIMP-2 
We demonstrated that C-terminal truncated cdMTl-MMP 
initiates activation of progelatinase A and progelatinase A 
complexed with TIMP-2 in vitro. Processing was monitored 
by SDS gels and gelatin zymography (Figs. 2 and 3). In ge- 
latin substrate gels the 72 kDa progelatinase migrates as two 
faint bands, one at 68 kDa representing progelatinase A acti- 
vated during the development of the zymogram by SDS [25], 
and a second one at 62 kDa originating possibly from auto- 
activation during the preparation (see Fig. 3B). Purified 
cdMTl-MMP itself also demonstrated gelatinolytic activity 
in the zymogram. However, for an equal proteolytic degrada- 
tion of gelatin an enzyme level higher than that of gelatinase 
A was required. As shown in Fig. 3B lane 2 cdMTl-MMP 
dependent activation of progelatinase A followed a two step 
mechanism. The catalytic domain of MTl-MMP initially 
cleaved progelatinase A into a 64 kDa fragment, which was 
subsequently processed to a 62 kDa product. N-terminal se- 
quence analysis of both gelatinase A fragments (5 cycles) re- 
vealed Leu38 for the 64 kDa intermediate and Tyrsl for the 62 
kDa species. The minor fragment is known to be the final 
autocatalytic cleavage product when exposed to APMA [lo]. 
Densitometric analysis of gelatinase A activation showed that 
5 min after incubation with cdMTl-MMP at 37°C the percen- 
tage of proMMP-2 decreases to 23%. 1 h after incubation at 
37°C the proform totally disappeared; the active form repre- 
sents 48% of the reaction mixture. A distinct difference in the 
rate and extent of activation of the 72 kDa progelatinase was 
observed by treatment of the TIMP-2 free and TIMP-2 com- 
plexed proenzyme with cdMTl-MMP for varying time peri- 
ods (Figs. 2 and 3). TIMP-2 free progelatinase A was more 
rapidly converted to lower molecular weight species than the 
TIMP-2 complexed form of the 72 kDa progelatinase. 
Furthermore, an excess amount of cdMTl-MMP was needed 
to activate the progelatinase A/TIMP-2 complex because the 
complex is a strong inhibitor for active MMPs [19,26]. 
3.3. Kinetic studies 
In kinetic experiments we found that cdMTl-MMP cleaved 
the synthetic fluorogenic substrate Mca-Pro-Leu-Gly-Leu- 
Dpa-Ala-Arg-NH* at the Gly-Leu bond. The initial linear 
rates of peptide hydrolysis by a constant amount of cdMTl- 
MMP were determined in the presence of six different con- 
centrations of the substrate. The resulting data were used in a 
Lineweaver-Burk plot (Fig. 4), from which the K,,, value of 
5.65 f 0.26 PM (k,,JK, = 8.27 X lo8 s-l M-l) was calculated. 
In the case of MMP-2 the K,,, for the hydrolysis of Mca-Pro- 
Leu-Gly-Leu-Dpa-Ala-Arg-NH2 was reported to be 70 PM 
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(k&K, =6.29X 10” s-l M-l) [20] and 3.86 f0.6 PM (k,,,l 
Km = 1.69 X lo* s-l M-l) for the catalytic domain of MMP- 
8 (M. Pieper, personal communication). This kinetic study 
revealed that the C-terminal truncated membrane-type metal- 
loproteinase generally behaves like other catalytic domains of 
the MMP family because their Km values and their values of 
the specificity constants k,,JK,,, were comparable. Compari- 
son of the values of k,,/K, for the catalytic domain of MT1 - 
MMP and full-length MMP-2, however, showed that effi- 
ciency of substrate catalysis by cdMTl-MMP is increased 
lOO-fold. These kinetic parameters must reflect a more favor- 
able binding of the Mea substrate. The equilibrium inhibition 
constant for bovine TIMP-2 and cdlMT-MMP was deter- 
mined in a similar manner. The addition of increasing 
amounts of TIMP-2 to a constant amount of cdMTl-MMP 
resulted in a decrease in enzyme activity. The Ki value of 
TIMP-2 (104 PM) was determined from Dixon plots (Fig. 
5). Our study indicated that TIMP-2 has a high affinity for 
cdMTl-MMP. It is evident that the C-terminal domain of 
MTl-MMP is not essential for inhibitor binding. 
4. Discussion 
4.1. Activation of MTI-MMP 
Our in vitro studies revealed that the zymogen form of 
MTl-MMP can be converted to the catalytic active enzyme 
(independent of other proteases or organomercury com- 
pounds) in an autocatalytic process. We found the amino- 
terminal residue of the mature protein to be Ile”*. (Ala’l- 









Fig. 3. Activation of progelatinase A complexed with TIMP-2 by 
cdMTl-MMP.The 72 kDa progelatinase A/TIMP-2 complex (210 ng 
samples each) was incubated -tith an excess of cdMTl-MMP fo; 
varving times at 37°C. It was then analvzed bv SDS-PAGE (10% 
acr$akide). Lane 1: protein M, markers (low range standaids); 
lane 2: cdMTI-MMP; lanes 3-5: proMMP-Z/TIMP-2 complex in 
the presence of cdMTl-MMP incubated at 37°C for 15, 30 and 60 
min respectively; lane 6: control: proMMP-2/TIMP-2 complex, in- 
cubation at 37°C for 60 min without cdMTl-MMP. 
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Fig. 4. Lineweaver-Burk plot for the digestion of the quenched 
fluorescent substrate Mea-Pro-Leu-Gly-Leu-Dpa-Ala-Arg-NH2 by 
the catalytic domain of MTl-MMP. Assays were conducted under 
the conditions described in Section 2. The digestion of the Mea pep- 
tide was measured at six different substrate concentrations. Values 
are the means of three determinations. 
such a degree that we failed to isolate the proform under non- 
denaturing conditions. The fact that the generated catalytic 
domain remains intact and keeps its activity even after storage 
at room temperature for several days could perhaps be ex- 
plained by an optimal stabilization of the enzyme conforma- 
tion. The N-terminal residue of most fully processed MMPs is 
often a phenylalanine or tyrosine, with the exception of mouse 
metalloelastase (leucine) [27]. From the crystal structure of the 
‘superactive’ catalytic domain of neutrophil collagenase 
(MMP-8) it is known [28] that the N-terminal Phe7g interacts 
with Asp 232 through a surface-located salt bridge formed be- 
tween the N-terminal ammonium group and the carboxylate 
of Asp232 which is strictly conserved in collagenases, resulting 
in an optimal conformation for catalytic activity. In the cat- 
alytic domain of MTl-MMP a tandem of three aspartates N- 
terminal of the putative ‘Met-turn’ occurs. Thus, it can per- 
haps be assumed that in a topologically equivalent manner the 
ammonium group of Ileg forms a salt bridge with the carbox- 
ylate moiety of one of these conserved aspartates. So far this 
phenomenon of ‘superactivation’ has only been observed in 
species having Phe7g as N-terminal residue of the active form 
[29-311. It remains to be determined whether MT-MMPs are 
processed by similar autocatalytic mechanisms in vivo. A 
number of studies have pointed out that MTl-MMP, like 
stromelysin-3, displays a four residue consensus sequence 
(RRKR or RQKR in stromelysin-3) which constitutes a pro- 
spective cleavage site for the subtilisin-like serine protease 
furin. Pei and Weiss determined that activation of MTl- 
MMP occurred by a proprotein convertase dependent path- 
way and found that the final cleavage site is the Arg111-Tyr112 
peptide bond [16]. 
4.2. Activation of progelatinase A and progelatinase A 
complexed with TIMP-2 
Observations that progelatinase A could be activated by 
components of fibroblast cell membranes led to the proposal 
that the in vivo activation might be a specific cell surface event 
[11,32]. During cell membrane-induced processing a progela- 
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Fig. 5. Dixon plot for the inhibition of cdMTl-MMP by TIMP-2. 
A Constant amount of truncated MTl-MMP (14 nM) was incubated 
with increasing amounts of TIMP-2 (O-9 nM) for 15 min at 37°C 
and assayed &r its ability to cleaver the flubrescent Mea peptide 
substrate. Inhibition experiments were carried out at three different 
substrate concentrations. Values are the means of four experiments. 
tinase A intermediate cleaved at Asn37-Leu38 had been identi- 
fied, which is further cleaved at Amso-Tyrsl. The possibility of 
a plasma membrane based activation process for the 72 kDa 
progelatinase has recently been substantiated by the impor- 
tant discovery of membrane-bound MMPs [13]. Strongin and 
co-workers [24] demonstrated that the formation of a ternary 
complex consisting of progelatina’se A, TIMP-2 and activated 
MTl-MMP is necessary for proMMP-2 activation. Moreover, 
Cao et al. [14] stated that the C-terminal transmembrane do- 
main is required as an essential structural element for the 
proteolytic activation of progelatinase A. In contrast to the 
above mentioned investigation the results of our in vitro stud- 
ies demonstrate that processing of proMMP-2 to its mature 
form by MTl-MMP is independent of cell surface localization 
of the enzyme. cdMTl-MMP can initiate proMMP-2 activa- 
tion via a two step mechanism: the cleavage of the Asn37- 
Leu38 peptide bond is followed by a cleavage of the Amso- 
Tyr*’ bond generating fully active gelatinase A. The precise 
mechanism of proMMP-2 activation in vivo is complicated by 
the presence of TIMP-2. Strongin et al. [24] recently reported 
that the MTl-MMPITIMP-2 complex acts as the surface re- 
ceptor for the gelatinase zymogen. The data presented here 
suggest that TIMP-2 and MMP-ZITIMP-2 complex are phys- 
iological inhibitors of MTl-MMP. It is likely that activation 
of proMMP-2 is a very complex process. Knowledge of the 
TIMP-2 binding affinities of both enzymes would help to clar- 
ify these still unsolved interactions. 
4.3. Inhibition of cdMTI-MMP by TIMP-2 
Among the well known MMP antagonists including chelat- 
ing agents, substrate analogues and az-macroglobulin the 
TIMPs probably have the most physiological relevance. 
Strongin et al. [24] reported that latent progelatinase A may 
bind to cell surface receptors (MTl-MMP) by interaction with 
TIMP-2. They suggested further that activation of proMMP-2 
would require an assembly of a trimolecular stoichiometric 
complex involving the C-terminus of MMP-2, TIMP-2 and 
MTl-MMP. Small amounts of TIMP-2 should increase the 
affinity of MTl-MMP for progelatinase A. An excess of 
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TIMP-2 completely inhibited proMMP-2 binding. Stronging 
and coworkers concluded that the cell surface receptor (MTl- 
MMP) saturated with TIMP-2 would not be able to bind the 
proMMP-2/TIMP-2 complex. Our present results show that 
the catalytic domain is able to activate proMMP-2 in the 
absence of TIMP-2. It can therefore be concluded that activa- 
tion of proMMP-2 may be independent of a plasma mem- 
brane associated trimolecular non-covalent complex of 
MTl-MMPITIMP-2 and progelatinase A and could proceed 
easily by shedded MTl-MMP. Furthermore, we found that 
TIMP-2 exerts a strong inhibitory effect on cdMTl-MMP 
with a ki value in the picomolar range. These results support 
the contention that the regulation of progelatinase A activa- 
tion probably cannot be explained by a simple model of a 
trimolecular complex. Our observations point to the involve- 
ment of multiple factors in the regulation of progelatinase A 
activation. We suggest that to maintain proenzyme converting 
activity, the balance of proteases (MTl-MMP, progelatinase 
A and probably additional, unidentified ones) and inhibitors 
(TIMPs) is essential. It is conceivable that cell-cell interactions 
might influence this balance between MMPs and TIMPs. 
Note added in proof: A paper on activation of progelatinase 
A by a soluble form of MTl-MMP cornfirming these results 
appeared by Will, H., Atkinson, S.J., Butler, G.S., Smith, B. 
and Murphy, G. (1996) J. Biol. Chem. 271, 17119-17123. 
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